Marie Schoumacher
Marie Schoumacher
Servier
Verified email at servier.com
Title
Cited by
Cited by
Year
Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia
M Schoumacher, RD Goldman, D Louvard, DM Vignjevic
Journal of Cell Biology 189 (3), 541-556, 2010
5022010
Fascin, a novel target of β-catenin-TCF signaling, is expressed at the invasive front of human colon cancer
D Vignjevic, M Schoumacher, N Gavert, KP Janssen, G Jih, M Laé, ...
Cancer research 67 (14), 6844-6853, 2007
2982007
Cancer-associated fibroblasts induce metalloprotease-independent cancer cell invasion of the basement membrane
A Glentis, P Oertle, P Mariani, A Chikina, F El Marjou, Y Attieh, F Zaccarini, ...
Nature communications 8 (1), 1-13, 2017
1692017
Key roles of AXL and MER receptor tyrosine kinases in resistance to multiple anticancer therapies
M Schoumacher, M Burbridge
Current oncology reports 19 (3), 1-14, 2017
752017
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
J Bertran-Alamillo, V Cattan, M Schoumacher, J Codony-Servat, ...
Nature communications 10 (1), 1-14, 2019
512019
ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor
Z Mounir, JM Korn, T Westerling, F Lin, CA Kirby, M Schirle, G McAllister, ...
Elife 5, e13964, 2016
472016
ETV5 cooperates with LPP as a sensor of extracellular signals and promotes EMT in endometrial carcinomas
E Colas, L Muinelo-Romay, L Alonso-Alconada, M Llaurado, M Monge, ...
Oncogene 31 (45), 4778-4788, 2012
472012
Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status
M Schoumacher, S Le Corre, A Houy, E Mulugeta, MH Stern, ...
Nature medicine 22 (6), 577-578, 2016
462016
Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling
M Schoumacher, KE Hurov, J Lehár, Y Yan-Neale, Y Mishina, D Sonkin, ...
Cancer research 74 (12), 3294-3305, 2014
382014
Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma
G Carita, E Frisch-Dit-Leitz, A Dahmani, C Raymondie, N Cassoux, ...
Oncotarget 7 (23), 33542, 2016
372016
Cytoskeleton networks in basement membrane transmigration
M Schoumacher, D Louvard, D Vignjevic
European journal of cell biology 90 (2-3), 93-99, 2011
352011
The mTOR inhibitor everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
N Amirouchene-Angelozzi, E Frisch-Dit-Leitz, G Carita, A Dahmani, ...
Oncotarget 7 (17), 23633, 2016
272016
Epithelial morphogenesis and intestinal cancer: new insights in signaling mechanisms
S Fre, D Vignjevic, M Schoumacher, SL Duffy, KP Janssen, S Robine, ...
Advances in cancer research 100, 85-111, 2008
232008
Conditional expression of fascin increases tumor progression in a mouse model of intestinal cancer
M Schoumacher, F El-Marjou, M Laé, N Kambou, D Louvard, S Robine, ...
European journal of cell biology 93 (10-12), 388-395, 2014
202014
Upcoming translational challenges for uveal melanoma
AA Nabil, S Marie, S Marc-Henri, C Nathalie, D Laurence, PN Sophie, ...
British journal of cancer 113 (9), 1249-1253, 2015
192015
Basement membrane invasion assays: native basement membrane and chemoinvasion assay
M Schoumacher, A Glentis, VV Gurchenkov, DM Vignjevic
Adhesion Protein Protocols, 133-144, 2013
182013
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
EM Algarín, A Díaz-Tejedor, P Mogollón, S Hernández-García, ...
haematologica 105 (3), e116, 2020
172020
AXL controls directed migration of mesenchymal triple-negative breast cancer cells
O Zajac, R Leclere, A Nicolas, D Meseure, C Marchiò, A Vincent-Salomon, ...
Cells 9 (1), 247, 2020
102020
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
R Thijssen, ST Diepstraten, D Moujalled, E Chew, C Flensburg, MX Shi, ...
Blood, The Journal of the American Society of Hematology 137 (20), 2721-2735, 2021
62021
Cotargeting BCL-2 and MCL-1 in high-risk B-ALL
DM Moujalled, DT Hanna, S Hediyeh-Zadeh, G Pomilio, L Brown, ...
Blood advances 4 (12), 2762-2767, 2020
62020
The system can't perform the operation now. Try again later.
Articles 1–20